Abbott’s fourth-generation MitraClip device was approved by the FDA July 15 to treat mitral regurgitation (MR) in a wider population of patients, the company announced this week.

Heavy air pollution in China could be contributing to a greater instance of coronary atherosclerosis among the country’s general population, according to research out of the University of Buffalo.

Edoxaban and warfarin are equally effective in reducing the risk of stroke, systemic embolic events and major bleeding in patients with atrial fibrillation and a history of liver disease, researchers reported in the Journal of the American College of Cardiology this month.

Researchers in Italy are developing “smart,” photo-responsive materials they hope will replicate the mechanical properties of a human heart in an artificial format, Cosmos Magazine reported July 12.

The Centro Nacional de Investigaciones Cardiovasculares, a research foundation in Madrid, Spain, has coordinated the first international consensus document to streamline MRI protocol after myocardial infarction in clinical trials and experimental models.

A study published in the Journal of the American Heart Association this month identified marriage as a predictor of better short- and long-term outcomes in patients with ACS, most notably male patients.

The Center to Advance Palliative Care suggests steps cardiologists can take to ensure ongoing identification and management of remediable sources of suffering and distress in heart failure patients.

The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.